Monitoring Agency Report for the quarter ended 31st March, 2026
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals has fully utilized the entire Rs. 114.30 crore raised through preferential issue of convertible share warrants. The funds were deployed across three objects: Capital Expenditure (Rs. 63.41 crore), Working Capital (Rs. 40 crore), and General Corporate Purposes (Rs. 10.89 crore). CARE Ratings, the monitoring agency, noted a minor reallocation where Rs. 0.54 crore was diverted from GCP to Capex, but this remained below the 10% materiality threshold and was within shareholder-approved limits. All payments were routed through the monitoring account and verified by the statutory auditor. No delays in implementation were reported.
Positive for shareholders - the company has transparently deployed all warrant proceeds as intended with only minor inter-object reallocations that are within permissible limits. This indicates proper fund management and compliance with SEBI regulations.